1 |
Yuen YP, Lai CK, Poon WT, Ng SW, Chan AY, Mak TW. Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat. Hong Kong Med J 2007;13:216-20.
|
2 |
Tang MH, Chen SP, Ng SW, Chan AY, Mak TW. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol 2011;71:250-3.
DOI
|
3 |
Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998;22 Suppl 1:S30-5; discussion S36-7, S42.
|
4 |
von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007;28:2830-1.
DOI
|
5 |
Scheen AJ. Sibutramine on cardiovascular outcome. Diabetes Care 2011;34 Suppl 2:S114-9.
DOI
|
6 |
Yim KM, Ng HW, Chan CK, Yip G, Lau FL. Sibutramine-induced acute myocardial infarction in a young lady. Clin Toxicol (Phila) 2008;46:877-9.
DOI
|
7 |
Ernest D, Gershenzon A, Corallo CE, Nagappan R. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother 2008;42:1514-7.
DOI
|
8 |
Eroglu E, Gemici G, Bayrak F, Kalkan AK, Degertekin M. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int J Cardiol 2009;137:e43-5.
DOI
|
9 |
Gomez-Barrado JJ, Turegano S, Garciperez de Vargas FJ, Porras Y. Acute coronary syndrome in a young woman treated with sibutramine. Rev Esp Cardiol 2010;63:243.
|
10 |
Harrison-Woolrych M, Clark DW, Hill GR, Rees MI, Skinner JR. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006;61:464-9.
DOI
|
11 |
Poss J, Bohm M, Link A. [32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine]. Dtsch Med Wochenschr 2010;135:965-8.
DOI
|
12 |
Fernandez WG, Biswas AK. Myocardial infarction associated with sibutramine use: case report and discussion. Mil Med 2010;175:622-4.
DOI
|
13 |
James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17.
DOI
|
14 |
Williams G. Withdrawal of sibutramine in Europe. BMJ 2010;340:c824.
DOI
|
15 |
Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf 2011;34:641-50.
DOI
|
16 |
Colman E. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation 2012;125:2156-64.
DOI
|
17 |
Muller D, Weinmann W, Hermanns-Clausen M. Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int 2009;106:218-22.
|
18 |
Sayin T, Guldal M. Sibutramine: possible cause of a reversible cardiomyopathy. Int J Cardiol 2005;99:481-2.
DOI
|